

# Marina Stolina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10407040/publications.pdf>

Version: 2024-02-01

61  
papers

8,135  
citations

66343

42  
h-index

123424

61  
g-index

61  
all docs

61  
docs citations

61  
times ranked

8395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163.	30.7	1,161
2	Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 860-869.	2.8	828
3	Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis. <i>Journal of Immunology</i> , 2000, 164, 361-370.	0.8	440
4	Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. <i>Bone</i> , 2012, 50, 209-217.	2.9	396
5	Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 182-195.	2.8	351
6	APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. <i>Nature Immunology</i> , 2000, 1, 252-256.	14.5	334
7	Taci Is a Traf-Interacting Receptor for Tall-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation. <i>Journal of Experimental Medicine</i> , 2000, 192, 137-144.	8.5	239
8	Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5056-5062.	3.6	234
9	Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1012-1021.	2.8	230
10	Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in <i>ldlr</i> <sup>−/−</sup> Mice. <i>Circulation</i> , 2008, 117, 411-420.	1.6	228
11	Î <sup>9</sup> -Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway. <i>Journal of Immunology</i> , 2000, 165, 373-380.	0.8	225
12	Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2647-2656.	2.8	208
13	A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. <i>Nature Communications</i> , 2016, 7, 11505.	12.8	200
14	Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo. <i>Journal of Immunology</i> , 2000, 164, 4558-4563.	0.8	199
15	Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. <i>Blood</i> , 2002, 100, 2330-2340.	1.4	178
16	Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 865-874.	2.8	126
17	Intratumoral Administration of Adenoviral Interleukin 7 Gene-Modified Dendritic Cells Augments Specific Antitumor Immunity and Achieves Tumor Eradication. <i>Human Gene Therapy</i> , 2000, 11, 53-65.	2.7	124
18	Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2021, 143, 120-134.	1.6	123

#	ARTICLE	IF	CITATIONS
19	Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. <i>Arthritis and Rheumatism</i> , 2009, 60, 1427-1437.	6.7	121
20	RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 672-682.	2.8	119
21	Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2610-2621.	2.8	106
22	Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 627-638.	2.8	105
23	RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1756-1765.	2.8	94
24	Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-21.	3.0	92
25	Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. <i>Bone</i> , 2011, 49, 162-173.	2.9	91
26	Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. <i>Bone</i> , 2014, 67, 305-313.	2.9	85
27	Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats. <i>Endocrinology</i> , 2011, 152, 3312-3322.	2.8	81
28	Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1732-1736.	0.9	81
29	Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?. <i>Journal of Biological Chemistry</i> , 2010, 285, 28164-28173.	3.4	77
30	RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF $\alpha$ or anti-IL-1 therapies. <i>Arthritis Research and Therapy</i> , 2009, 11, R187.	3.5	75
31	The Evolving Systemic and Local Biomarker Milieu at Different Stages of Disease Progression in Rat Adjuvant-Induced Arthritis. <i>Journal of Clinical Immunology</i> , 2009, 29, 158-174.	3.8	69
32	Tumor necrosis factor $\alpha$ and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2644-2654.	6.7	68
33	Increased RANK ligand in bone marrow of orchietomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. <i>Bone</i> , 2009, 45, 669-676.	2.9	67
34	Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. <i>Bone</i> , 2015, 81, 380-391.	2.9	67
35	Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody. <i>Endocrinology</i> , 2014, 155, 4785-4797.	2.8	65
36	Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses. <i>Journal of Immunology</i> , 2007, 179, 7497-7505.	0.8	62

#	ARTICLE	IF	CITATIONS
37	Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1158-1169.	2.8	61
38	Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. <i>Arthritis and Rheumatism</i> , 2005, 52, 1604-1611.	6.7	58
39	Analysis of the kinetics of osteoclastogenesis in arthritic rats. <i>Arthritis and Rheumatism</i> , 2005, 52, 3192-3201.	6.7	58
40	Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 618-626.	2.8	46
41	Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function. <i>Journal of Immunology</i> , 2002, 168, 5690-5698.	0.8	45
42	Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice. <i>Journal of Immunology</i> , 2001, 166, 5578-5584.	0.8	43
43	Local Delivery of Recombinant Osteoprotegerin Enhances Postorthodontic Tooth Stability. <i>Calcified Tissue International</i> , 2012, 90, 330-342.	3.1	41
44	Regulatory effects of osteoprotegerin on cellular and humoral immune responses. <i>Clinical Immunology</i> , 2003, 109, 347-354.	3.2	40
45	One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1234-1246.	2.8	40
46	Transient muscle paralysis degrades bone <i>via</i> rapid osteoclastogenesis. <i>FASEB Journal</i> , 2012, 26, 1110-1118.	0.5	37
47	Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. <i>Bone</i> , 2012, 50, 628-637.	2.9	34
48	Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. <i>Calcified Tissue International</i> , 2017, 101, 641-653.	3.1	34
49	Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. <i>Journal of Orthopaedic Research</i> , 2014, 32, 197-203.	2.3	32
50	Early Response of Bone Marrow Osteoprogenitors to Skeletal Unloading and Sclerostin Antibody. <i>Calcified Tissue International</i> , 2012, 91, 50-58.	3.1	29
51	The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. <i>Biomarkers</i> , 2008, 13, 692-712.	1.9	28
52	Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 171-181.	2.8	27
53	RANKL Inhibition: From Mice to Men (and Women). <i>Advances in Experimental Medicine and Biology</i> , 2007, 602, 143-150.	1.6	25
54	RANKL-targeted therapy inhibits bone resorption in experimental <i>Staphylococcus aureus</i> -induced arthritis. <i>Bone</i> , 2010, 46, 752-758.	2.9	23

#	ARTICLE	IF	CITATIONS
55	Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5). <i>Bone</i> , 2018, 107, 161-171.	2.9	23
56	Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. <i>Biomarkers</i> , 2008, 13, 79-87.	1.9	22
57	Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation. <i>Bone</i> , 2020, 130, 115047.	2.9	14
58	Rapid Skeletal Turnover in a Radiographic Mimic of Osteopetrosis. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2601-2609.	2.8	12
59	Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. <i>Bone</i> , 2021, 145, 115835.	2.9	7
60	Response to Letter Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in <i>ldlr</i> ( $\Delta/\Delta$ ) Mice". <i>Circulation</i> , 2008, 118, .	1.6	4
61	Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1774-1782.	2.8	3